Condiciones de salud que astaxantina puede ayudar a apoyar.
Astaxanthin (ASX) is a xanthophyll carotenoid with well-documented antioxidant activity supported by multiple human clinical trials. It directly scavenges reactive oxygen species (ROS) and upregulates endogenous antioxidant enzymes—including superoxide dismutase (SOD) and total antioxidant capacity (TAC)—primarily through activation of the Nrf2/ARE signaling pathway. A 2025 systematic review of 15 human studies confirmed consistent reductions in oxidative stress indices and increases in antioxidant capacity across diverse populations. Doses in human trials have ranged from approximately 4–20 mg/day over 3–12 weeks.
Astaxanthin is a carotenoid antioxidant with documented vascular protective effects. PubMed-indexed reviews identify it among antioxidants providing vascular protection. Clinical studies show it reduces oxidized LDL, lipid peroxidation, and arterial inflammatory markers. It crosses the blood-vessel wall to quench ROS that degrade NO, supporting endothelial function.
Astaxanthin's anti-inflammatory properties (inhibiting NF-κB, reducing IL-6, TNF-α, and COX-2) provide a mechanistic basis for arthritis benefit. Animal studies confirm reductions in joint inflammation and cartilage degradation markers. Human evidence is indirect, drawn from trials showing systemic anti-inflammatory effects; no dedicated human arthritis RCTs have been published.
Astaxanthin is a powerful carotenoid antioxidant found in microalgae that has shown ergogenic effects in RCTs, including improved cycling power output, reduced oxidative stress after exercise, and decreased exercise-induced muscle damage. Multiple controlled trials in athletes support its use for performance and recovery.
Astaxanthin, a marine carotenoid from Haematococcus pluvialis, has powerful antioxidant and immunomodulatory properties studied in rheumatoid arthritis and multiple autoimmune inflammatory conditions. It reduces pro-inflammatory cytokines, inhibits NF-κB, and modulates T-cell and macrophage activity. Human trials show reductions in inflammatory biomarkers.
Human evidence is mixed: meta-analyses of 5 RCTs found no statistically significant effect on systolic or diastolic blood pressure overall, yet a 2025 cardiovascular review noted human trials suggest positive effects on blood pressure control, particularly through improved endothelial function. Animal data is more robust, showing significant SBP reductions in spontaneously hypertensive rats.
Multiple RCTs and a 2026 meta-analysis of 6 RCTs (n=292) demonstrate astaxanthin significantly reduces fasting blood glucose (WMD: −16.1 mg/dL) and HbA1c in prediabetes and type 2 diabetes patients. A 12-week double-blind RCT (n=53) showed improved 2-hour glucose on OGTT and improved Matsuda insulin sensitivity index. The mechanism involves reduction of oxidative stress and inflammation that impair insulin signaling.
A 2023 review (PMC10376010) summarized in vitro, animal, and emerging human data showing astaxanthin enhances osteoblast differentiation, inhibits osteoclast activity, and increases bone mineral density. Animal studies confirm BMD and trabecular bone microarchitecture recovery after 6 weeks of ASX supplementation. Human clinical data remain limited but support the mechanistic pathway.
Astaxanthin is a marine xanthophyll carotenoid with potent antioxidant activity that reduces oxidative stress-mediated chondrocyte damage in OA. In vitro and animal studies demonstrate astaxanthin suppresses IL-1β–induced MMP expression and NF-κB signaling in chondrocytes. An open-label pilot study in OA patients found 12 mg/day astaxanthin for 8 weeks significantly improved VAS pain scores and WOMAC function.
Astaxanthin supports mitochondrial function by reducing mitochondrial oxidative damage, improving fatty acid β-oxidation efficiency, and protecting the electron transport chain from ROS-mediated impairment. Human exercise trials show improved endurance and reduced fatigue, consistent with enhanced cellular energy metabolism. Preclinical data in osteoblasts and muscle cells confirm mitochondrial function improvement.
Multiple RCTs and meta-analyses demonstrate astaxanthin reduces total cholesterol and LDL-C while raising HDL-C. A 2023 RCT in prediabetic/dyslipidemic subjects found significant decreases in total cholesterol (−0.30 mM, p=0.027) and LDL (−0.33 mM, p=0.030) vs. placebo. Meta-analysis confirms these effects with small-to-moderate effect sizes.
Astaxanthin is a powerful carotenoid antioxidant produced by Haematococcus pluvialis microalgae, clinically studied for reducing exercise-induced fatigue and oxidative stress. Multiple RCTs and animal studies demonstrate reduced physical fatigue, improved endurance, and reduced inflammatory markers. It protects mitochondrial membranes from oxidative damage central to fatigue pathophysiology.
Astaxanthin, a xanthophyll carotenoid, has demonstrated anti-inflammatory effects in multiple human randomized controlled trials, reducing key biomarkers including CRP, IL-6, and TNF-α. A meta-analysis of 14 clinical trials confirmed its efficacy in lowering CRP, with significant effects observed at doses above 12 mg/day for durations of 12 weeks or more. A 2025 systematic review of 15 human studies found consistent reductions in pro-inflammatory cytokines and oxidative stress indices. Evidence is promising but overall trial sizes remain small and long-term data are limited.
Astaxanthin has documented effects on vascular endothelial function in human studies: it reduces oxidative stress and inflammation biomarkers relevant to atherosclerosis, and RCTs report improvements in endothelial function markers in adults. Evidence from a 2025 comprehensive review confirms improved vascular health outcomes across clinical trials.
Astaxanthin, a marine xanthophyll carotenoid, has human clinical trial evidence supporting modest improvements in memory and psychomotor performance in middle-aged and older adults. Its ability to cross the blood–brain barrier and act as a potent antioxidant and anti-inflammatory agent underpins its proposed neuroprotective mechanism. Evidence is promising but limited by small sample sizes and few large RCTs, with most strong mechanistic data still preclinical.
Astaxanthin is a potent carotenoid antioxidant listed among active compounds studied for periorbital hyperpigmentation management, including in a peer-reviewed review (Pigment International, 2024). It was incorporated in a randomized double-blind placebo-controlled under-eye dark circle clinical study. Its main mechanism is protecting periorbital skin from oxidative stress that promotes melanogenesis.
A small US RCT (n=28, 12 mg/day, 8 weeks) found a 57% reduction in self-rated depression scores and improvements in overall mood, although subjects were non-clinically depressed at baseline. A PMC narrative review notes that while animal studies support antidepressant-like effects through neuroinflammation reduction, human clinical evidence remains limited and of modest certainty.
A prospective quasi-experimental clinical study (n=60 patients, 120 eyes, Beijing Tongren Hospital) found oral astaxanthin 6 mg twice daily for 30 days significantly improved OSDI, TBUT, corneal fluorescein staining, and meibomian gland function in mild-to-moderate DED. It crosses the blood-retinal barrier and inhibits HMGB1, TNF-α, and IL-1β in corneal epithelial cells.
Human RCTs have shown astaxanthin improves exercise endurance and reduces mental fatigue. A 2025 BMC Sports RCT found significantly longer time-to-exhaustion in the ASX group (28 mg/day, 4 days) during cycling. An 8-week trial reported a 36% reduction in mental fatigue. ASX may enhance mitochondrial fat oxidation, partially explaining improved energetic efficiency.
Astaxanthin is a ketocarotenoid derived from Haematococcus pluvialis microalgae with multiple clinical trials demonstrating benefits for digital eye strain and visual fatigue. A 2025 randomized, double-blind, placebo-controlled trial (n=64 children, 4 mg/day, 84 days) in Advances in Therapy found a 20% reduction in computer vision syndrome symptoms and a 27% improvement in visual fatigue versus placebo. Multiple adult trials also show improved accommodative amplitude, retinal blood flow, and ciliary muscle function.
Small clinical trials show astaxanthin may improve sperm motility and reduce semen oxidative stress in infertile men, with one RCT (n=30, 16 mg/day, 3 months) reporting a 54.5% pregnancy rate vs. 10.5% placebo. However, a 2026 systematic review and meta-analysis of 3 human RCTs found no statistically significant improvement in semen parameters overall, indicating mixed and low-certainty human evidence.
A 2023 triple-blind RCT in women with endometriosis undergoing ART showed ASX reduced oxidative stress, inflammation, and improved reproductive outcomes. In PCOS, a 60-day treatment modulated ER stress in granulosa cells. A 2025 systematic review confirmed ASX downregulated ER stress-related apoptotic pathways and improved oocyte and embryo quality in women with PCOS or endometriosis.
Human RCTs support modest improvements in cognitive performance including psychomotor speed and processing relevant to focus. An 8-week US clinical trial (12 mg/day, n=28) showed significant improvements in overall mood state and mental fatigue reduction, both of which influence concentration. Cognitive review data suggests benefits depend on age, dose, and test method.
Astaxanthin is a ketocarotenoid produced by the microalga Haematococcus pluvialis with antioxidant potency far exceeding that of vitamin E or beta-carotene. Multiple Japanese RCTs found that 6 mg/day of astaxanthin improved visual acuity, reduced eye fatigue, and enhanced accommodative function in VDT workers. A 2022 PMC study found it reduces dry eye inflammation by suppressing HMGB1 and inflammatory cytokines.
Astaxanthin is a marine xanthophyll carotenoid with potent antioxidant and anti-inflammatory properties demonstrated in multiple clinical trials. Human studies at 4–12 mg/day report improvements in skin aging biomarkers (hydration, elasticity, wrinkle depth), cognitive function in older adults, and reduced oxidative stress markers. A 2025 PubMed review (n>2,000 participants across trials) confirmed tolerability and broad anti-aging activity.
Astaxanthin is a marine xanthophyll carotenoid that crosses the blood-retinal barrier and protects ocular tissues via potent antioxidant and anti-inflammatory activity. Multiple human RCTs at doses of 4–12 mg/day show improvements in visual fatigue, accommodative function, and retinal parameters in aging adults. Research also suggests protection of lens crystallin proteins from oxidative damage relevant to cataract.
Meta-analysis of RCTs found astaxanthin did not significantly affect BMI (SMD: −0.02; p=0.821), and most individual trials show no meaningful weight reduction. However, in obesity models and some human trials, ASX reduces adipose tissue inflammation and improves metabolic markers such as insulin sensitivity and lipid profiles that accompany weight-related conditions.
Astaxanthin, a xanthophyll carotenoid, has human clinical evidence supporting cardiovascular benefits primarily through antioxidant and anti-inflammatory mechanisms. RCT-level data show favorable effects on HDL cholesterol and triglycerides, reduced inflammatory markers (CRP), and improved endothelial function. Pilot studies also indicate improvements in cardiac function and exercise tolerance in heart failure patients. Evidence is promising but limited by small sample sizes and short trial durations, and large-scale cardiovascular endpoint trials are still lacking.
ASX reduces insulin resistance measured by HOMA-IR across multiple human RCTs, with the strongest effects observed at the hepatic level. In PCOS patients (n=58, 12 mg/day, 8 weeks), it significantly reduced HOMA-IR and fasting insulin. Mechanistically, it enhances antioxidant capacity (SOD, TAC) and lowers oxidative markers that disrupt insulin signaling.
A randomized double-blind placebo-controlled trial (6 mg/day, 8 weeks) in renal transplant patients found astaxanthin was safely consumed without adverse effects on renal function. Preclinical evidence demonstrates astaxanthin protects against kidney oxidative damage; diabetic retinopathy cell studies confirm renal-parallel antioxidant pathways. However, dedicated human RCTs with renal endpoints are sparse.
A 2026 systematic review of human trials suggests astaxanthin's primary organ for insulin sensitization may be the liver, with improvements in hepatic insulin resistance index observed. Animal studies confirm protection of liver tissue in PCOS models, and preclinical data show ASX reduces non-alcoholic fatty liver markers. Limited but emerging human evidence supports hepatic benefit.
Astaxanthin is a ketocarotenoid with antioxidant potency approximately 10-fold greater than zeaxanthin and lutein, capable of spanning the full lipid bilayer to protect both hydrophilic and hydrophobic membrane zones. The multicenter CARMIS trial (n=145, 24-month RCT) found a formulation including 4 mg astaxanthin with lutein, zeaxanthin, and antioxidants stabilized visual acuity and improved contrast sensitivity in AMD patients compared to controls.
Human RCTs report modest but significant improvements in memory and cognitive performance in middle-aged and older adults at 6–12 mg/day for 8–12 weeks. A Japanese RCT found improvements in memory test scores in healthy volunteers with age-related mild forgetfulness. Benefits are attributed to astaxanthin crossing the blood-brain barrier and reducing neuronal oxidative stress.
Multiple randomized controlled trials (RCTs) and at least two systematic reviews/meta-analyses have directly investigated astaxanthin supplementation in adults with metabolic syndrome (MetS) risk factors. The strongest pooled finding is a significant reduction in LDL-cholesterol, with marginal effects on total cholesterol and systolic blood pressure. Combined with exercise, astaxanthin also improved body composition, lipid profiles, and insulin sensitivity. Evidence is real but still limited in scale, and individual study results remain inconsistent.
Astaxanthin is a ketocarotenoid with exceptionally potent antioxidant properties—100× more powerful than vitamin E at quenching singlet oxygen—that concentrates in mitochondrial membranes to protect against lipid peroxidation and oxidative damage to the ETC. Studies show it preserves mitochondrial membrane potential and reduces ROS production.
Multiple human RCTs have examined astaxanthin for exercise-induced muscle damage with mixed results. A 2025 dose-response RCT (n=32, 4 weeks) found 12 and 24 mg/day significantly reduced MDA and TNF-α post-exhaustive exercise vs. placebo. However, a 2023 Frontiers in Nutrition clinical trial found little effect of 4-week ASX on exercise-induced inflammation markers, illustrating inconsistency in the human literature.
A 2025 dose-response RCT found 12–24 mg/day of astaxanthin for 4 weeks reduced exercise-induced muscle soreness compared with placebo. A PMC 2025 RCT in resistance-trained men confirmed astaxanthin reduced subjective markers of delayed-onset muscle soreness (DOMS) following eccentric exercise. Effect magnitude varies by dose and training status.
Astaxanthin is a potent carotenoid antioxidant that crosses the blood-brain barrier and blood-retinal barrier, demonstrating neuroprotective properties in preclinical and human studies. Clinical trials show benefits for cognitive function, neural fatigue, and neuroprotection against oxidative stress.
Astaxanthin accumulates in ocular tissues including the retina and has demonstrated protective effects on retinal photoreceptor cells and retinal microcirculation in human and animal studies. RCTs in adults ≥40 years show improvements in visual acuity and accommodative function at 4–9 mg/day. Retinal protective mechanisms via oxidative stress reduction have been confirmed in cell studies.
Astaxanthin is a powerful xanthophyll carotenoid from Haematococcus pluvialis with anti-inflammatory and antioxidant properties relevant to bone health. Preclinical studies show astaxanthin inhibits osteoclast differentiation and reduces inflammatory cytokine-driven bone resorption. It has been identified in nutraceutical osteoporosis reviews as an emerging bone-protective antioxidant.
Evidence for Parkinson's disease is currently preclinical and mechanistic: astaxanthin has been shown in cell-based and animal studies to modulate oxidative stress, neuroinflammation, and apoptosis in dopaminergic neurons. A 2025 review (Frontiers in Aging Neuroscience) confirms potential neuroprotective effects in PD models, but no human RCTs in PD patients have been completed.
Multiple human RCTs document astaxanthin's benefits in PCOS: a triple-blind RCT (n=58, 12 mg/day, 8 weeks) found significant reductions in fasting glucose, HOMA-IR, LDL-C, oxidative stress markers and increased HDL-C and antioxidant capacity. A 2026 systematic review further confirmed improvements in ovarian granulosa cell function and metabolic parameters in PCOS patients.
Astaxanthin is a powerful carotenoid antioxidant that has been studied in multiple RCTs for physical endurance. It reduces exercise-induced oxidative stress and muscle damage, improves fat oxidation during exercise, and has been shown to improve cycling time trial performance and increase time to exhaustion in human studies. Typically studied at 4–20 mg/day.
A potent carotenoid antioxidant (500–6,000× more powerful than vitamin C against singlet oxygen), astaxanthin from Haematococcus pluvialis has documented anti-inflammatory and immune-enhancing properties. Clinical evidence shows it reduces oxidative stress and supports immune recovery from exercise- and disease-induced stress.
Astaxanthin is a ketocarotenoid antioxidant from Haematococcus pluvialis that inhibits NF-κB, reduces IL-6 and TNF-α, and provides antioxidant protection relevant to RA oxidative stress. It is included in krill oil (a studied RA supplement) and in stand-alone joint health formulas; preclinical evidence in arthritis models supports its anti-inflammatory activity.
Astaxanthin, a ketocarotenoid from Haematococcus pluvialis, has been studied in a randomized, double-blind, placebo-controlled trial for skin aging. A 16-week RCT (n=65 women, ages 35–60) showed significant reduction in wrinkle grade and improved skin elasticity and moisture versus placebo. It inhibits UV-induced MMP-1 and MMP-2 expression and quenches singlet oxygen in dermal tissue.
Astaxanthin is a carotenoid antioxidant with clinical evidence for protecting skin collagen and elastin from UV-induced degradation. A 16-week clinical study in 65 healthy females showed suppression of UVB-induced MMP-1 secretion and inflammatory cytokines. When combined with collagen hydrolysate, astaxanthin improved facial elasticity and decreased MMP-1/-12 expression versus placebo.
A 2020 human RCT (PMC7093296) assessed astaxanthin-rich extract on stress and sleep in adults, with improvements in mood subscales linked to stress and fatigue. The 8-week US RCT also showed significant reductions in tension (−20%) and anger (−12%). Preclinical and human evidence together suggest a mild adaptogenic-like effect on psychological stress markers.
A carotenoid antioxidant from Haematococcus pluvialis microalgae with multiple human RCTs demonstrating protection against UV-induced skin deterioration. A 16-week RCT in 65 healthy women (6 mg or 12 mg/day) showed astaxanthin prevented worsening of wrinkle parameters and skin moisture that occurred in placebo. A 2020 systematic review of 11 clinical studies found 3–6 mg/day for 4–16 weeks protected against UV-induced damage and minimized photoaging signs.
Meta-analyses of RCTs consistently show astaxanthin significantly reduces serum triglycerides. One meta-analysis (SMD: −0.17; p=0.033) confirmed this effect alongside reductions in total cholesterol and LDL-C. High-dose supplementation (20 mg/day, 12 weeks) in obese males produced statistically significant triglyceride reductions versus placebo.
Astaxanthin is a red keto-carotenoid with potent antioxidant and immunomodulatory properties. It enhances NK cell activity, T cell proliferation, and antibody production. Clinical studies support its role in reducing oxidative damage during viral infection and modulating immune responses; it has shown preliminary evidence for reducing cold and flu severity.
Volver